Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma.
about
Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspectiveSystemic therapies for pancreatic cancer--the role of pharmacogeneticsEvolution of systemic therapy for advanced pancreatic cancer.Gemcitabine for the treatment of advanced nonsmall cell lung cancerGene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models.Clinical pharmacology and pharmacogenetics of gemcitabine.Stratification of nucleoside analog chemotherapy using 1-(2'-deoxy-2'-18F-fluoro-β-D-arabinofuranosyl)cytosine and 1-(2'-deoxy-2'-18F-fluoro-β-L-arabinofuranosyl)-5-methylcytosine PET.Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy?Noninvasive prediction of tumor responses to gemcitabine using positron emission tomographyGenomics and pharmacogenomics of pancreatic adenocarcinoma.Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge.Expression of gemcitabine- and cisplatin-related genes in non-small-cell lung cancer.Complementary effects of HDAC inhibitor 4-PB on gap junction communication and cellular export mechanisms support restoration of chemosensitivity of PDAC cells.Cytidine deaminase single-nucleotide polymorphism is predictive of toxicity from gemcitabine in patients with pancreatic cancer: RTOG 9704.Correlation between cytidine deaminase genotype and gemcitabine deamination in blood samples.G-CSF mobilized PBMCs contribute to the liver function of cirrhotic rats.Fluorinated nucleosides as an important class of anticancer and antiviral agents.MiR-608 regulating the expression of ribonucleotide reductase M1 and cytidine deaminase is repressed through induced gemcitabine chemoresistance in pancreatic cancer cells.Selection of the best blood compartment to measure cytidine deaminase activity to stratify for optimal gemcitabine or cytarabine treatment.
P2860
Q26752368-B1CA359F-A547-4B34-B5B3-FC6C7FBCD31FQ27021716-695A35A2-FF7B-4B09-97CC-68595CD3009EQ33557413-1343CF90-6D4E-48CF-9BE0-3737C279CE3AQ33915997-C1EB93B9-E17D-4DDF-91FD-1E4A2624CCD3Q34177223-E871E442-538D-488A-9AB4-1C261FC3A418Q34792522-DFFAC8E6-8DA6-40DC-8265-1DB0E6FE967EQ34985979-243CEBD8-46E5-4024-BEB9-DCBE3C149954Q36201693-54C16066-1830-448A-AEF5-A0074128F289Q36610851-5EF643E7-5C29-4649-B638-B366BF9843F9Q37085729-3BCFAE77-9016-4BA3-9F7D-C2EFF27234C3Q37970279-AA7A2369-6AAD-4F77-B64D-34CD3D5BA3D4Q37994505-A420BA1A-7211-4CC6-9C21-3901236F57BDQ39776948-FD1ECC32-660A-42EC-A2F9-85E71BE170B8Q40197237-D0E06BDA-9C00-46F5-B40B-42DA8FC23529Q44546647-267063CC-CB6C-431E-B542-08E0DAC8F813Q46502249-6A963DDC-568B-414C-BAFE-83E6F100873BQ47171947-F25E4296-05BA-48D3-A671-09A380C1AF7EQ47637142-E7485345-B86E-4812-8EC9-71CC6580A8DBQ47830761-9722F749-9254-4F06-A3C3-A0CB1690DEB3Q50468405-3D57209B-A380-439C-9458-F033B0F26CAE
P2860
Prolonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Prolonged fixed dose rate infu ...... ced pancreatic adenocarcinoma.
@ast
Prolonged fixed dose rate infu ...... ced pancreatic adenocarcinoma.
@en
type
label
Prolonged fixed dose rate infu ...... ced pancreatic adenocarcinoma.
@ast
Prolonged fixed dose rate infu ...... ced pancreatic adenocarcinoma.
@en
prefLabel
Prolonged fixed dose rate infu ...... ced pancreatic adenocarcinoma.
@ast
Prolonged fixed dose rate infu ...... ced pancreatic adenocarcinoma.
@en
P2093
P2860
P50
P356
P1476
Prolonged fixed dose rate infu ...... nced pancreatic adenocarcinoma
@en
P2093
M Del Chiaro
M Del Tacca
M Lencioni
P2860
P2888
P356
10.1038/SJ.BJC.6602673
P407
P577
2005-07-01T00:00:00Z